The risk of high-frequency hearing loss in children undergoing cancer treatment to the central nervous system or the head and neck could be reduced by minimising doses of radiation to the cochlea and limiting cumulative doses of cisplatin or carboplatin, Canadian researchers say.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.